Global EVAR Stent Grafts Market Size By Type (Abdominal Aortic Stent Grafts, Thoracic Aortic Stent Grafts), By Application (Ruptured AAA Treatment, Traumatic Aortic Injury Treatment), By Region, And S...

The Global EVAR (Endovascular Aneurysm Repair) Stent Grafts Market was valued at USD 2.4 billion in 2023 and is expected to reach USD 4.7 billion by 2031, growing at a CAGR of 8.8% during the forecast period from 2023 to 2031. This growth is primarily driven by the increasing prevalence of abdominal aortic aneurysms (AAA), advancements in stent graft technologies, and a rising preference for minimally invasive surgical procedures. EVAR stent grafts offer lower perioperative morbidity, reduced hospital stay, and faster recovery compared to open surgery, making them a preferred choice in vascular interventions.

Drivers:

1. Rising Incidence of Abdominal Aortic Aneurysms:

The global burden of AAA, particularly among aging populations, is significantly boosting the demand for EVAR procedures. Early detection through advanced imaging and growing health awareness is contributing to the rapid adoption of stent graft systems.

2. Technological Advancements in Stent Grafts:

Continuous innovation in materials, design, and deployment systems—such as fenestrated and branched stent grafts—is enhancing procedural outcomes and expanding the treatable patient population.

3. Increasing Preference for Minimally Invasive Surgeries:

Minimally invasive vascular procedures offer numerous benefits including reduced recovery time, fewer complications, and lower mortality rates, which is driving the adoption of EVAR over traditional open surgery.

Restraints:

1. High Cost of EVAR Procedures and Devices:

The elevated cost of EVAR stent grafts and associated imaging technologies can limit accessibility, especially in lower-income and underinsured populations.

2. Risk of Long-Term Complications and Reinterventions:

Despite advancements, issues such as endoleaks and device migration can occur, necessitating follow-up procedures and deterring widespread adoption in complex anatomies.

Opportunity:

1. Untapped Potential in Emerging Markets:

Growing investments in healthcare infrastructure and increased screening for vascular diseases in regions like Asia-Pacific and Latin America offer significant growth opportunities for market players.

2. Integration of Imaging and AI in EVAR Planning:

The convergence of AI and 3D imaging technologies is revolutionizing pre-surgical planning, offering more precise patient-specific graft selection and improving surgical outcomes.

Market by System Type Insights:

Based on system type, the Standard EVAR Stent Grafts segment accounted for the largest market share in 2023. These devices remain the mainstay for infrarenal AAA treatment due to their wide applicability and established clinical outcomes. However, the Fenestrated and Branched EVAR (F/BEVAR) segment is expected to grow at the fastest rate, driven by increasing demand for treating complex aneurysms involving branch vessels.

Market by End-use Insights:

By end-use, Hospitals held the largest share in 2023, owing to their access to advanced imaging, multidisciplinary surgical teams, and integrated vascular care facilities. The Ambulatory Surgical Centers (ASCs) segment is poised to grow significantly due to increasing adoption of minimally invasive procedures in outpatient settings, cost-efficiency, and reduced patient hospitalization.

Market by Regional Insights:

North America dominated the global EVAR stent grafts market in 2023, fueled by a high prevalence of aortic aneurysms, advanced healthcare infrastructure, and early adoption of innovative vascular technologies. However, Asia-Pacific is anticipated to witness the highest CAGR during the forecast period due to improved access to vascular care, rising healthcare expenditure, and growing aging populations in countries like China and India.

Competitive Scenario:

Prominent players in the Global EVAR Stent Grafts Market include Medtronic plc, Cook Medical, W. L. Gore & Associates, Inc., Terumo Corporation, Endologix LLC, MicroPort Scientific Corporation, Lombard Medical, and Bentley InnoMed GmbH. These companies are focusing on strategic collaborations, new product launches, and regulatory approvals to expand their global footprint and product offerings.

Key Developments:

In 2023, Medtronic received FDA approval for its next-generation Endurant II stent graft system optimized for challenging aortic anatomies.

Cook Medical launched its Zenith Fenestrated stent graft in new European markets, addressing the treatment of juxtarenal AAAs.

In 2024, Endologix announced a strategic partnership with AI software providers to enhance preoperative planning with real-time 3D visualization.

Scope of Work – Global EVAR Stent Grafts Market

Report Metric Details

Market Size (2023) USD 2.4 Billion

Projected Market Size (2031) USD 4.7 Billion

CAGR (2023-2031) 8.8%

Market Segments By System Type (Standard, F/BEVAR), By End-use (Hospitals, ASCs), By Region

Growth Drivers Rising AAA cases, Technological advancements, Shift to minimally invasive procedures

Opportunities Emerging markets, AI-based surgical planning tools

FAQs:

1. What is the current market size of the Global EVAR Stent Grafts Market?

The market was valued at USD 2.4 billion in 2023.

2. What is the major growth driver of the Global EVAR Stent Grafts Market?

The key growth driver is the rising prevalence of abdominal aortic aneurysms and the preference for minimally invasive procedures.

3. Which is the largest region during the forecast period in the Global EVAR Stent Grafts Market?

North America is the largest regional market, while Asia-Pacific is the fastest-growing.

4. Which segment accounted for the largest market share in the Global EVAR Stent Grafts Market?

The Standard EVAR Stent Grafts segment held the largest share in 2023.

5. Who are the key market players in the